Table 1.

Clinicopathological details according to COX-2 status

Table-1		COX-2 positive		COX-2 negative		Z-value	p-value
		No of patients	Percentage (%)	No of patients	Percentage (%)
Menopausal Status	Premenopausal	40	76.9	12	23.1	5.49	<0.01*
	Postmenopausal	64	90.1	7	9.9	9.56	<0.01*
Age (years)	≤50	52	78.8	14	21.1	6.61	<0.01*
	>50	52	91.2	5	8.8	8.80	<0.01*
Stage	I	8	66.7	4	33.3	1.63	>0.05
	II	13	81.3	3	18.8	3.53	<0.01*
	III	77	87.5	11	12.5	9.94	<0.01*
	IV	6	85.7	1	14.3	2.67	<0.01*
Tumor size (cm)	0 – 1.99	5	71.4	2	28.6	1.60	>0.05
	2 – 3.99	47	75.8	15	24.2	5.74	<0.01*
	≥ 4	52	96.3	2	3.7	9.62	<0.01*
Grade	I	2	22.2	7	77.8	2.35	<0.05*
	II	17	73.9	6	26.1	3.24	<0.01*
	III	85	93.4	6	6.6	11.71	<0.01*
Lymph node metastasis	No Node	4	26.7	11	73.3	2.55	<0.05*
	1 – 3 Node	35	81.4	8	18.6	5.82	<0.01*
	4 – 9 Node	47	100.0	0	0.0	9.69	<0.01*
	10 – More Node	18	100.0	0	0.0	6.00	<0.01*
NPI	< 5.4	18	48.6	19	51.4	0.23	>0.05
	≥ 5.4	86	100.0	0	0.0	13.11	<0.01*
ER	Positive	38	70.4	16	29.6	4.23	<0.01*
	Negative	66	95.7	3	4.3	10.72	<0.01*
PR	Positive	28	68.3	13	31. 7	3.31	<0.01*
	Negative	76	92.7	6	7.3	10.93	<0.01*
HER-2/neu	Positive	29	100.0	0	0.0	7.61	<0.01*
	Negative	75	79.8	19	20.2	8.16	<0.01*
Histology type	IDC	83	92.2	7	7.8	11.32	<0.01*
	LC	12	63.2	7	36.8	1.62	>0.05
	DCIS	9	64.3	5	35.7	1.51	>0.05

DCIS ductal carcinoma in situ, IDC invasive ductal carcinoma, LC lobular carcinoma

* Statistically significant